Gerald R. Ewoldt

Array ( [id] => 17110075 [patent_doc_number] => 20210290672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => REGULATION OF TUMOR-ASSOCIATED T CELLS [patent_app_type] => utility [patent_app_number] => 16/325923 [patent_app_country] => US [patent_app_date] => 2017-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9884 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16325923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12184081 [patent_doc_number] => 20180043017 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'PHARMACEUTICAL COMPOSITIONS COMPRISING 0.5 MG DOSE OF SYNTHETIC HUMAN PEPTIDES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS' [patent_app_type] => utility [patent_app_number] => 15/673642 [patent_app_country] => US [patent_app_date] => 2017-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 16804 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15673642 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12186788 [patent_doc_number] => 20180045724 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'METHODS OF DETECTING INFLAMMATORY MARKERS AND TREATING INFLAMMATORY CONDITIONS IN HUMANS' [patent_app_type] => utility [patent_app_number] => 15/674427 [patent_app_country] => US [patent_app_date] => 2017-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28379 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15674427 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14715607 [patent_doc_number] => 20190248867 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => MYELIN OLIGODENDROCYTE GLYCOPROTEIN-SPECIFIC PEPTIDE FOR THE TREATMENT OR PREVENTION OF MULTIPLE SCLEROSIS [patent_app_type] => utility [patent_app_number] => 16/314642 [patent_app_country] => US [patent_app_date] => 2017-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11466 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16314642 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16141519 [patent_doc_number] => 10703822 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-07 [patent_title] => Anti-inflammatory agents [patent_app_type] => utility [patent_app_number] => 15/630020 [patent_app_country] => US [patent_app_date] => 2017-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 26 [patent_no_of_words] => 16505 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15630020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16025897 [patent_doc_number] => 10675348 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-09 [patent_title] => Antibodies that bind human C6 and uses thereof [patent_app_type] => utility [patent_app_number] => 15/625790 [patent_app_country] => US [patent_app_date] => 2017-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 15 [patent_no_of_words] => 35470 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15625790 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12030840 [patent_doc_number] => 20170320939 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-09 [patent_title] => 'COLL2-1 PEPTIDE AND ITS NITRATED FORM AS THERAPEUTIC TARGETS FOR OSTEOARTHRITIS TREATMENT' [patent_app_type] => utility [patent_app_number] => 15/624801 [patent_app_country] => US [patent_app_date] => 2017-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 13036 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15624801 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14309645 [patent_doc_number] => 20190144526 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => Ig-pCONSENSUS GENE VACCINATION PROTECTS FROM ANTIBODY-DEPENDENT IMMUNE PATHOLOGY IN AUTOIMMUNE DISEASE [patent_app_type] => utility [patent_app_number] => 15/624086 [patent_app_country] => US [patent_app_date] => 2017-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9337 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15624086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13691893 [patent_doc_number] => 20170356901 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-14 [patent_title] => T CELL-BOUND CYTOKINE ASSAY FOR ANTIGEN-SPECIFIC TOLERANCE [patent_app_type] => utility [patent_app_number] => 15/618648 [patent_app_country] => US [patent_app_date] => 2017-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8902 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15618648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11963586 [patent_doc_number] => 20170267740 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'PEPTIDES ASSOCIATED WITH HLA-DR MHC CLASS II MOLECULE AND INVOLVED IN RHEUMATOID ARTHRITIS' [patent_app_type] => utility [patent_app_number] => 15/608711 [patent_app_country] => US [patent_app_date] => 2017-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 12883 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15608711 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16362413 [patent_doc_number] => 20200319164 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => METHODS FOR DETECTING, ASSESSING SEVERITY AND TREATING MULTIPLE SCLEROSIS [patent_app_type] => utility [patent_app_number] => 16/303771 [patent_app_country] => US [patent_app_date] => 2017-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6463 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16303771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12049868 [patent_doc_number] => 20170326213 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-16 [patent_title] => 'Protein-Coupled Red Blood Cell Compositions and Methods of Their Use' [patent_app_type] => utility [patent_app_number] => 15/596586 [patent_app_country] => US [patent_app_date] => 2017-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 10860 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15596586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11864798 [patent_doc_number] => 20170232084 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'IMMUNE MODULATION FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION' [patent_app_type] => utility [patent_app_number] => 15/584108 [patent_app_country] => US [patent_app_date] => 2017-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 35134 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15584108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12001862 [patent_doc_number] => 20170306017 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'ANTI-CD100 ANTIBODIES AND METHODS FOR USING THE SAME' [patent_app_type] => utility [patent_app_number] => 15/581573 [patent_app_country] => US [patent_app_date] => 2017-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 38564 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15581573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11948266 [patent_doc_number] => 20170252417 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-07 [patent_title] => 'PROTEIN-CHAPERONED T-CELL VACCINES' [patent_app_type] => utility [patent_app_number] => 15/452266 [patent_app_country] => US [patent_app_date] => 2017-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 26799 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15452266 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17143035 [patent_doc_number] => 20210311048 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => Anti-CXC chemokine receptor antibodies and C-X-C chemokines for the diagnosis of autoimmune disease and graft-versus-host disease [patent_app_type] => utility [patent_app_number] => 16/077915 [patent_app_country] => US [patent_app_date] => 2017-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31402 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16077915 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13926209 [patent_doc_number] => 20190046620 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => THERAPEUTIC INDUCTION OF TOLERANCE USING RECOMBINANT CELL SURFACE ANTIGENS [patent_app_type] => utility [patent_app_number] => 16/077386 [patent_app_country] => US [patent_app_date] => 2017-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12388 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16077386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15038585 [patent_doc_number] => 20190330297 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => INSULIN GENE-DERIVED PROTEINS AND PEPTIDES FOR USE IN THE DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES [patent_app_type] => utility [patent_app_number] => 16/071900 [patent_app_country] => US [patent_app_date] => 2017-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18671 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16071900 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15205939 [patent_doc_number] => 20190365656 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => PARTICLES ENCAPSULATING FUSION PROTEINS CONTAINING LINKED EPITOPES [patent_app_type] => utility [patent_app_number] => 16/067867 [patent_app_country] => US [patent_app_date] => 2017-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26281 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -106 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16067867 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11514301 [patent_doc_number] => 20170081375 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-23 [patent_title] => 'GENERATION OF BRAIN AND SPINAL CORD NEURONS, CARDIAC MYOCYTES, RENAL NEPHRONS AND HEPATOCYTES USING REG PEPTIDES, PEPTIDOMIMETICS, SMALL MOLECULES AND STIMULATORY ANTIBODIES TO REG RECEPTOR' [patent_app_type] => utility [patent_app_number] => 15/369685 [patent_app_country] => US [patent_app_date] => 2016-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 18103 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15369685 [rel_patent_id] =>[rel_patent_doc_number] =>)